“…The neurotransmitter orexin A, known for regulation of various physiological functions (such as appetite and sleep), has been correlated with obsessive-compulsive (measured by SRI) and extrapyramidal symptoms, that may accompany disease progression (cross-sectional, N = 40) ( Roveta et al, 2022 ). Lastly, specific metabolic changes were found in bvFTD (compared to controls), such as altered metabolites in a wide range of pathways (including amino acids, energy and carbohydrate, cofactor and vitamin, lipid and nucleotide) and increased fat preference, offering a new field to reveal possible physiological progression markers ( N = 30, N = 20) ( Murley et al, 2020 ; Ahmed et al, 2021 ). However, for all suggested fluid biomarkers, e.g., NfL, sTREM2, GFAP, Orexin A as well as metabolic features, longitudinal observations are needed and highly recommended, before they can be evaluated in their potential to track disease progression.…”